Abstract:OBJECTIVE:Single chain antibody-mediated delivery is a novel approach for targeting shRNA to appropriate cells. In this report, we studied whether this shRNA delivery strategy would be effective against rabies virus.METHODS:Rabies virus scFv (G) gene and ETA-GAL4 gene were amplified by PCR from vector scFv (G)-T and PE40-GAL4-T respectively. Then, the chimeric gene scFv (G)-ETA-GAL4 was constructed by lapextension PCR and cloned into the prokaryotic expression vector pET28a( +). Recombinant expression plasmid of pET28a(+)-scFv(G)-ETA-GAL4 was constructed and then transformed into the competent E. coli BL21 (DE3) cells for expression under the induction of IPTG. scFv(G)-ETA-GAL4 protein was purified by Ni-NTA His Bind Resin affinity chromatograph and identified by SDS-PAGE gel and Western blot assay. Binding of the fusion protein scFv(G)-ETA-GAL4 to rabies virus was determined by ELISA. Complexes which formed spontaneously by the fusion protein scFv(G)-ETA-GAL4 with plasmid pRNATU6.3-shRNA were added to BHK-21 cells culture medium that infected with RV. Green fluorescent protein (GFP) was observed after 35 h and judged the transferring efficiency of the complexes. The inhibition of RV replication by shRNA was detected by direct immune fluorescence test.RESULTS:A 1557 bp DNA encoding scFv (G)-ETA-GAL4 protein gene was cloned and successfully expressed in inclusion body with approximate molecular weight of 57.0 kDa, which could be recognized by anti-His mAb. The scFv(G)-ETA-GAL4 proteins were purified by Ni-NTA column , and after renatured with the yield of 2.8 mg/mL. The ELISA results showed that when concentration of the scFv(G)-ETA-GAL4 protein ranging from 2.8 nmol/L to 1000 nmol/L, binding affinity is directly related with RV. The GFP expressed in BHK-21 cell after transfection with the complexes and effectively inhibited RV replication in BHK-21 cell.CONCLUSION:scFv(G)-ETA-GAL4 fusion protein could mediated plasmid pRNATU6.3-shRNA transferred into BHK-21 cell infected with RV, and then inhibited RV replication.

Drug Repurposing for Rabies Treatment: A Computational Analysis of 14 Agents

In silico structural elucidation of the rabies RNA-dependent RNA polymerase (RdRp) toward the identification of potential rabies virus inhibitors

Clofazimine: A Promising Inhibitor of Rabies Virus

Rabies Prophylactic and Treatment Options: An In Vitro Study of siRNA- and Aptamer-Based Therapeutics

Mechanism of action of phthalazinone derivatives against rabies virus

Fine mapping and interaction analysis of a linear rabies virus neutralizing epitope.

Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach

Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein

Artesunate and Dihydroartemisinin Inhibit Rabies Virus Replication

A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis

Drug Repurposing For SARS-COV-2 Using Molecular Docking

Repurposing raltegravir for reducing inflammation and treating cancer: a bioinformatics analysis

Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs

Bufotenine, a tryptophan-derived alkaloid, suppresses the symptoms and increases the survival rate of rabies-infected mice: the development of a pharmacological approach for rabies treatment

Preexposure and Postexposure Prophylaxis of Rabies With Adeno-Associated Virus Expressing Virus-Neutralizing Antibody in Rodent Models

Repurposing of approved antivirals against dengue virus serotypes: an in silico and in vitro mechanistic study

[Targeted Inhibition of Rabies Virus Replication in Vitro by Single Chain Antibody Domain Mediated Vector Expression Shrna Delivery].

Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals

A molecular dynamics simulations analysis of repurposing drugs for COVID-19 using bioinformatics methods

Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies

Molecular Engineering of AIE Photosensitizers for Inactivation of Rabies Virus